Newer insulin analogs: advances in basal insulin replacement (Q38085332)

28 August 2017

Newer insulin analogs: advances in basal insulin replacement (English)

1 reference

28 August 2017

1 reference

1

Bernard Zinman

1 reference

28 August 2017

1 March 2013

1 reference

Diabetes, Obesity and Metabolism

28 August 2017

1 reference

28 August 2017

15 Suppl 1

1 reference

28 August 2017

6-10

1 reference

The physiologic replacement of insulin. An elusive goal

28 August 2017

1 reference

Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes

21 January 2018

1 reference

Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs

21 January 2018

1 reference

A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes

21 January 2018

1 reference

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

21 January 2018

1 reference

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.

21 January 2018

1 reference

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review

21 January 2018

1 reference

Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

21 January 2018

1 reference

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

21 January 2018

1 reference

Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus

21 January 2018

1 reference

Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study

21 January 2018

1 reference

Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials

21 January 2018

1 reference

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

21 January 2018

1 reference

Barriers to insulin initiation: the translating research into action for diabetes insulin starts project

21 January 2018

1 reference

Three-year efficacy of complex insulin regimens in type 2 diabetes

21 January 2018

1 reference

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

Correlates of insulin injection omission

21 January 2018

1 reference

Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine

21 January 2018

1 reference

Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).

21 January 2018

1 reference

Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.

21 January 2018

1 reference

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

The worldwide diabetes epidemic

21 January 2018

1 reference

Globalization of diabetes: the role of diet, lifestyle, and genes

21 January 2018

1 reference

US trends in glycemic control, treatment, and comorbidity burden in patients with diabetes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12068

1 reference

28 August 2017

1 reference

PubMed ID

23448197